Core Viewpoint - Apple Inc is experiencing positive momentum with a new partnership with Google and strong expectations for first-quarter financial results, supported by analyst optimism [1][2] Group 1: Analyst Insights - Bank of America analyst Wamsi Mohan maintains a Buy rating on Apple stock with a price target of $325, indicating confidence in the company's performance [1] - Mohan anticipates strong iPhone sales and expanding gross margins for both the December and March quarters, suggesting a bullish outlook ahead of earnings [2] - The analyst expects first-quarter revenue to exceed estimates, driven by robust iPhone sales and double-digit growth in Services revenue [2] Group 2: iPhone Sales Projections - Mohan estimates that Apple sold 85 million iPhones in the first fiscal quarter, an increase of 2 million units from previous estimates, and raises the second-quarter estimate to 54 million units [3] - Year-over-year iPhone revenue growth is projected at 17% for the first quarter, marking one of the best quarters for the smartphone [3] Group 3: Future Catalysts and Challenges - Looking ahead to 2026, rising memory costs are identified as a potential challenge, but deemed manageable [4] - Key upcoming catalysts include the launch of a foldable iPhone in the fall and an enhanced Siri integrated with Gemini AI, which could drive higher upgrade rates [4] Group 4: Investor Sentiment - Current investor sentiment towards Apple stock is relatively negative, attributed to higher memory costs affecting the tech sector [5] - Apple is currently underweight in investor portfolios, but this trend is expected to reverse in the coming year [5] - As of Monday, Apple stock is trading at $260.25, up 0.34%, with an 11.3% increase over the last 52 weeks [5]

U.S. banks and financial institutions on Monday pushed back against President Donald Trump's proposed cap on credit card interest rates, citing new data that showed it would result in millions of Ame... ...

The major lenders on Wall Street will start the fourth-quarter earnings season this week while shareholders monitor their financial reports to understand the direction of the sector for 2026. JPMorgan... ...

Group 1 - Standard Chartered is planning to launch a prime brokerage for cryptocurrency trading as part of its SC Ventures unit [1] - The bank previously launched spot trading for Bitcoin and Ethereum in July 2025, claiming to be the first global systemically important bank to do so for institutional clients [2] - Standard Chartered offers various digital asset services, including transactions, custody, and tokenization solutions for institutional clients [3] Group 2 - The decision to explore crypto trading services comes amid a trend of major banks, such as JPMorgan Chase and Bank of America, entering the cryptocurrency space [5] - Prime brokerage services will include financing, securities lending, and custody to help investors manage risks and trade efficiently [8] - Discussions regarding the launch of the crypto brokerage are still in the early stages, with no confirmed timeline for its introduction [8]

Market Performance - U.S. stocks showed mixed trading, with the Nasdaq Composite gaining over 50 points, while the Dow decreased by 0.19% to 49,411.94, and the S&P 500 rose by 0.04% to 6,969.38 [1] - Consumer staples shares increased by 1%, while financial stocks dipped by 1.1% [1] Commodities - Oil prices fell by 0.7% to $58.72, while gold prices rose by 2.5% to $4,612.70 [5] - Silver increased by 7.1% to $84.970, and copper rose by 1.1% to $5.9655 [5] European Markets - European shares were generally higher, with the eurozone's STOXX 600 gaining 0.21%, Spain's IBEX 35 Index rising 0.12%, and London's FTSE 100 increasing by 0.16% [6] Asian Markets - Asian markets closed higher, with Hong Kong's Hang Seng Index gaining 1.44%, China's Shanghai Composite rising 1.09%, and India's BSE Sensex increasing by 0.36% [7] Company Updates - Day One Biopharmaceuticals Inc (NASDAQ:DAWN) shares surged 20% to $10.77, reporting preliminary 2025 OJEMDA net product revenue of $155.4 million, up 172% year over year [9] - Rxsight Inc (NASDAQ:RXST) shares increased by 12% to $9.88, announcing preliminary fourth-quarter revenue of $32.6 million [9] - SunOpta Inc (NASDAQ:STKL) shares rose by 18% to $4.38 after raising its FY2025 sales guidance [9] - Atara Biotherapeutics Inc (NASDAQ:ATRA) shares dropped 53% to $6.41 following an FDA Complete Response Letter citing clinical trial adequacy concerns [9] - Lyra Therapeutics Inc (NASDAQ:LYRA) shares fell 51% to $1.84 after announcing plans to suspend development of its lead product candidate and implement workforce reductions [9] - Lexeo Therapeutics Inc (NASDAQ:LXEO) shares decreased by 28% to $7.60 after announcing interim Phase I/II data for its treatment candidate [9]

Market Performance - U.S. stocks showed mixed trading, with the Nasdaq Composite gaining over 50 points, while the Dow decreased by 0.19% to 49,411.94 and the S&P 500 rose by 0.04% to 6,969.38 [1] - Consumer staples shares increased by 1%, while financial stocks dipped by 1.1% [1] Commodities - Oil prices fell by 0.7% to $58.72, while gold prices rose by 2.5% to $4,612.70 [5] - Silver increased by 7.1% to $84.970, and copper rose by 1.1% to $5.9655 [5] European Markets - European shares were higher, with the eurozone's STOXX 600 gaining 0.21%, Spain's IBEX 35 Index rising 0.12%, and London's FTSE 100 increasing by 0.16% [6] Asian Markets - Asian markets closed higher, with Hong Kong's Hang Seng Index gaining 1.44%, China's Shanghai Composite rising 1.09%, and India's BSE Sensex increasing by 0.36% [7] Company Updates - Day One Biopharmaceuticals Inc (NASDAQ:DAWN) shares surged 20% to $10.77, reporting preliminary 2025 OJEMDA net product revenue of $155.4 million, up 172% year over year [9] - Rxsight Inc (NASDAQ:RXST) shares increased by 12% to $9.88, announcing preliminary fourth-quarter revenue of $32.6 million [9] - SunOpta Inc (NASDAQ:STKL) shares rose by 18% to $4.38 after raising its FY2025 sales guidance [9] - Atara Biotherapeutics Inc (NASDAQ:ATRA) shares dropped 53% to $6.41 following an FDA Complete Response Letter citing clinical trial adequacy concerns [9] - Lyra Therapeutics Inc (NASDAQ:LYRA) shares fell 51% to $1.84 after announcing plans to suspend development of its lead product candidate and implement workforce reductions [9] - Lexeo Therapeutics Inc (NASDAQ:LXEO) shares decreased by 28% to $7.60 after announcing interim Phase I/II data for LX2020 [9]

Key Takeaways Bank stocks fell Monday after President Donald Trump said over the weekend that credit card interest rates should be capped at 10% for at least a year.How a cap would be put in place and why for only a year remains unclear. A number of banking and financial stocks slumped Monday morning after President Donald Trump over the weekend suggested capping credit card interest rates. Trump posted on social media late Friday that Americans are being "ripped off" by interest rates of 20% to 30%, a ...

Core Viewpoint - Bank of America (BAC) is expected to report strong fourth-quarter and full-year 2025 results, with revenue growth driven by trading and net interest income (NII) despite some challenges from interest rate cuts [1][2]. Financial Performance - BAC's nine-month performance was solid, with impressive trading numbers and growth in NII, leading to a projected revenue of $27.32 billion for Q4, indicating a 7.8% year-over-year growth [2][10]. - The consensus estimate for earnings has been revised 1% lower to 95 cents, reflecting a 15.9% increase from the prior-year quarter, supported by higher NII and a solid capital markets business [3]. Estimate Revision Trend - Current earnings estimates for Q4 2025 are 0.95, down from 0.96 a week ago, while estimates for the next quarter and the current year remain stable [5]. - BAC has a history of earnings surprises, having outperformed the Zacks Consensus Estimate in the last four quarters with an average surprise of 8.47% [5][6]. Factors Impacting Q4 Performance - NII is expected to be between $15.6 billion and $15.7 billion for Q4, suggesting an 8% year-over-year growth, despite recent Federal Reserve interest rate cuts [9]. - Loan demand has been robust, particularly in commercial, industrial, real estate, and consumer loans, which is expected to support BAC's performance [8]. Investment Banking (IB) and Trading Income - IB fees are projected to be "flattish to a little bit down" from last year, with a consensus estimate of $1.62 billion, indicating a 2% decline [13]. - Trading revenues are expected to rise by 23.3% year-over-year, driven by market volatility and increased client activity, with total sales and trading revenues estimated at $5.06 billion [15]. Expenses and Asset Quality - Non-interest expenses are anticipated to be around $17.3 billion for Q4, reflecting a 3.6% year-over-year increase due to expansion and digitization efforts [16]. - The provision for credit losses is estimated at $1.33 billion, with non-performing loans expected to increase by 6.6% year-over-year [17][18]. Stock Performance and Valuation - BAC shares gained 6.6% in Q4, outperforming the S&P 500, but lagging behind JPMorgan and Citigroup [22]. - The stock is trading at a price-to-tangible book (P/TB) ratio of 2.01X, below the industry average of 3.18X, indicating it is currently undervalued [25]. Strategic Outlook - The company is focusing on aggressive branch expansion and technology investments to drive future NII growth, with an expected growth rate of 6-7% for 2026 [29][30]. - Management's commentary on NII guidance and IB outlook during the upcoming earnings call will be crucial for investors [31].

Group 1 - Bank of America is set to release its fourth-quarter earnings on January 14, with analysts expecting earnings of 96 cents per share, an increase from 82 cents per share in the same period last year [1] - The consensus estimate for Bank of America's quarterly revenue is $27.62 billion, up from $25.35 billion reported in the previous year [1] - On January 7, 2026, TD Cowen analyst Steven Alexopoulos raised the price target for BAC stock from $64 to $66, maintaining a Buy rating [3] Group 2 - Bank of America announced the redemption of $3 billion in fixed/floating rate senior notes due January 2027 [2] - Shares of Bank of America fell 0.6% to close at $55.85 on the day of the announcement [2] - Goldman Sachs analyst Richard Ramsden increased the price target for BAC from $58 to $64 while maintaining a Buy rating on January 6, 2026 [3]

Market Analysis by covering: S&P 500, Citigroup Inc, Bank of America Corp, Goldman Sachs Group Inc. Read 's Market Analysis on Investing.com ...